RESEARCHER PROFILE
Georgina Hughes,
Pharmacist & PhD Candidate
University of South Australia Clinical and Health Sciences
Registry of Senior Australians (ROSA)
South Australian Health and Medical Research Institute
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
The study, published in the Journal of American Medical Directors Association (JAMDA), was led by Georgina, in collaboration with Professor Maria Inacio and Associate Professor Janet Sluggett. It’s Australia’s first national study investigating the use of antidepressants among older people living in residential aged care homes across the country, analysing the de-identified data of 779,659 residents from 3,371 aged care homes, between 2006 and 2019.
“We found antidepressants were used by 46.1% of residents in 2006 and this increased to 58.5% of residents in 2019,” Ms Hughes said.
“Nearly six in every ten residents of aged care homes are using an antidepressant, which is much higher than use in the general older population.”
The use of antidepressant medicines among older people in aged care homes in Australia is high, and there is a need for better mental health support and safer use of antidepressants to improve clinical care and health outcomes for older people.
Antidepressant medicines can have side effects, especially in older people, and Australia is one of the largest consumers globally.
Almost 60% of aged care home residents are using antidepressant medicines, prompting the need to investigate the reasons for such high usage.
Georgina talks to how big data is crucial in understanding and improving the use of antidepressant medicines in aged care, leading to better clinical care and health outcomes for older people in Australia.
Georgina is passionate about practice-informing, translational and innovative research to improve quality use of medicines and health outcomes.
-
Earlier identification and early intervention for children who are deaf or hard of hearing
As Director of NextSense Institute, Professor Leigh is responsible for leading the not-for-profit organisation’s world-class research and education programs and facilities. He has held a variety of positions in the education of children who are deaf or hard of hearing before entering academia. He holds a degree in Special Education from Griffith University, a Master of Science (Speech and Hearing) from Washington University and a PhD in Special Education from Monash University. In 2001, he was made a Fellow of the Australian College of Educators and in 2014, he was invested as an Officer in the Order of Australia (AO) for distinguished services to the deaf and hard of hearing community.
-
Impact of Leukaemia Foundation’s Research Funding into Blood Cancer
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
